Second-line treatment with axitinib showed superior PFS but not OS compared with sorafenib in metastatic renal cell carcinoma previously treated with cytokines, according to updated tiral results reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Single-agent carfilzomib is efficacious in patients with relapsed and double-refractory/intolerant multiple myeloma, according to updatedtrial results presented at the 2012 American Association of Clinical Oncology Annual Meeting.
Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Experts tell Chemotherapy Advisor that new consumer-targeted cancer-screening apps may put patients at risk.
